Hot Life Science Investor Mandate 3: Venture Capital Fund Seeking Early Stage Orphan Opportunities

9 Oct

​A Venture Capital fund formed by a partnership between a European pharmaceutical company and US based venture capital firm is currently looking to make seed and venture stage investments into life science companies ranging anywhere from $200K to $5 million initially and up to $8 million over the life of the investment. The fund is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.

​The fund is focused on rare and orphan diseases that affect less than 200,000 people throughout the United States. Within this area the fund is open to therapeutics and diagnostics across a number of technology types including, antibodies, small molecules, stem cells, cell therapy, gene therapy, vaccines, molecular diagnostics, and genomics among others. The fund is interested in companies anywhere from pre-clinical through phase III of clinical trials and has no preference for platform or single asset companies. The fund is not interested in biosimilars or generics.

​The fund is looking for privately held companies with experienced management teams. The fund looks to act as a hands on investor and seeks board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: